Share-based Payment Arrangement, Expense of Poseida Therapeutics, Inc. from 30 Jun 2019 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Poseida Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2019 to 30 Sep 2024.
  • Poseida Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2024 was $4,959,000, a 3.1% decline year-over-year.
  • Poseida Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2024 was $23,034,000, a 1.8% increase year-over-year.
  • Poseida Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $23,134,000, a 22% increase from 2022.
  • Poseida Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $18,926,000, a 13% increase from 2021.
  • Poseida Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $16,704,000, a 131% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Poseida Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $23,034,000 $4,959,000 -$158,000 -3.1% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $23,192,000 $7,629,000 +$2,155,000 +39% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2024 2024 Q2
Q1 2024 $21,037,000 $5,383,000 -$2,097,000 -28% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $23,134,000 $5,063,000 +$515,000 +11% 01 Oct 2023 31 Dec 2023 10-K 07 Mar 2024 2023 FY
Q3 2023 $22,619,000 $5,117,000 +$840,000 +20% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $21,779,000 $5,474,000 +$240,000 +4.6% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 $21,539,000 $7,480,000 +$2,613,000 +54% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $18,926,000 $4,548,000 +$199,000 +4.6% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q3 2022 $18,727,000 $4,277,000 +$126,000 +3% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $18,601,000 $5,234,000 +$492,000 +10% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $18,109,000 $4,867,000 +$1,405,000 +41% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $16,704,000 $4,349,000 +$2,149,000 +98% 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $14,555,000 $4,151,000 +$2,256,000 +119% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $12,299,000 $4,742,000 +$3,126,000 +193% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $9,173,000 $3,462,000 +$1,953,000 +129% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $7,220,000 $2,200,000 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $1,895,000 +$1,219,000 +180% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $1,616,000 +$1,009,000 +166% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $1,509,000 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q3 2019 $676,000 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $607,000 01 Apr 2019 30 Jun 2019 10-Q 20 Aug 2020 2020 Q2

Poseida Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $23,134,000 +$4,208,000 +22% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2024 2023 FY
2022 $18,926,000 +$2,222,000 +13% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 $16,704,000 +$9,484,000 +131% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $7,220,000 +$4,170,000 +137% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $3,050,000 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.